Graeme Moyle

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · The Lancet · 2008 · 482 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Éric Lefebvre, Graeme Moyle, Ran Reshef et al. · PLoS ONE · 2016 · 312 citations · Full text

Medicine, Immunology, Pharmacology +17

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

Graeme Moyle, Caroline Sabin, Jonathan Cartledge et al. · AIDS · 2006 · 273 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 255 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV‐1 Infection

Graeme Moyle, Adrian Wildfire, Sundhiya Mandalia et al. · The Journal of Infectious Diseases · 2005 · 228 citations

Life Sciences, Immunology, Infectious Diseases +17